Drugs / HRS5685
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05328583 | Apr 2022 → Mar 2023 | HIV infectious disease | RetroLead (Shanghai) BioPharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS5685 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05328583 ↗ |
| Route | Oral | “Oral HRS5685” NCT05328583 ↗ |